{Reference Type}: Journal Article
{Title}: Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
{Author}: Doshita K;Naito T;Matsuda S;Morita M;Sekikawa M;Miura K;Kodama H;Yabe M;Morikawa N;Iida Y;Mamesaya N;Kobayashi H;Ko R;Wakuda K;Ono A;Murakami H;Kenmotsu H;Takahashi T;
{Journal}: Thorac Cancer
{Volume}: 15
{Issue}: 25
{Year}: 2024 Sep 29
{Factor}: 3.223
{DOI}: 10.1111/1759-7714.15403
{Abstract}: <B>BACKGROUND: </B>Chemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy-induced anorexia and therapeutic outcomes in patients with stage IV non-small-cell lung cancer undergoing platinum-based chemotherapy combined with immune checkpoint inhibitors.<BR><B>METHODS: </B>The study retrospectively reviewed the medical records of 106 patients with stage IV non-small-cell lung cancer treated with platinum-based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy-induced anorexia group. Chemotherapy-induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression-free and overall survival were used to measure treatment efficacy.<BR><B>RESULTS: </B>Chemotherapy-induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non-chemotherapy-induced anorexia group. Progression-free and overall survival were shorter in the chemotherapy-induced anorexia group than in the non-chemotherapy-induced anorexia group, but the difference was not statistically significant.<BR><B>CONCLUSIONS: </B>Chemotherapy-induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non-small-cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy-induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum-based chemotherapy combined with immune checkpoint inhibitors.